Figure 4: CD19 monoclonal antibodies deplete B cells in vivo through macrophage-mediated antibody-dependent cellular ... of multiple immunosuppressive drugs rather than CD20 mAb alone, 51 this ...

ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs ...

FMC63, an IgG2a mouse monoclonal antibody, targets CD19. To date, a majority of the reported CART19 trials include the anti-CD19 scFv extracted from FMC63, such as both the FDA-approved CARs ...

A newly developed antibody-based molecule targets B-non-Hodgkin ... recently undergone a major transformation with the advent of CD19-targeted autologous CAR-T cell therapies," continued Demaria ...

Tafasitamab binds to CD19, a protein on the surface of B-cells ... Minjuvi's closest rival is actually Roche's antibody-drug conjugate Polivy (polatuzumab vedotin), which was approved for DLBCL ...

ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that Ameet Mallik, Chief Executive Officer, will ...

The big pharma is paying $100 million upfront for the company, and offering up to $805 million in milestone payments if TeneoTwo's drug ... antibody Blincyto (blinatumomab) for CD19-positive ...